• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Heart Association, Google collaborate on heart disease

Heart Association, Google collaborate on heart disease

November 12, 2015
CenterWatch Staff

The American Heart Association (AHA) and Google Life Sciences (GLS) have announced a joint commitment to form a research collaboration that will bring new, unconventional thinking to one of the longstanding challenges of cardiovascular disease. Each organization will invest $25 million for a total of $50 million over roughly five years to support novel strategies to understand, prevent and reverse coronary heart disease and its consequences, such as heart failure and sudden cardiac death.

Cardiovascular diseases are the leading cause of death globally, accounting annually for about 17 million deaths, or about one of every three deaths. Coronary heart disease itself is responsible for more than 7 million deaths annually. But the root causes of the disease continue to be explored and a concerted effort, combining technology and medicine, could help. Because traditional research funding models, which often are incremental and piecemeal, make it difficult to study a multifaceted subject that plays out over many years, AHA and GLS have committed to a bold new approach: a $50 million investment in one research team, which will be tasked with developing a richer, deeper understanding of cardiovascular disease.

That amount marks the largest one-time research investment in AHA’s history. In early 2016, a joint leadership group made up of individuals from AHA and GLS will select a team leader to run the effort. The team leader, who may be a cardiologist but could come from any background or area of expertise, will receive the full $50 million in funding over roughly five years to design a program, assemble a cross-functional group of investigators, and lead all efforts toward further finding new causes and drivers of coronary heart disease. The team will have support across many important areas, including clinical research, engineering, and data analysis, as well as ongoing strategic counsel, oversight and access to resources from the Joint Leadership Group.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing